ANI PHARMACEUTICALS INC (ANIP)
US00182C1036 - Common Stock
Overall ANIP gets a fundamental rating of 6 out of 10. We evaluated ANIP against 198 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of ANIP get a neutral evaluation. Nothing too spectacular is happening here. ANIP has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
ANIP had positive earnings in the past year.
ANIP had a positive operating cash flow in the past year.
In multiple years ANIP reported negative net income over the last 5 years.
ANIP had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
ANIP has a Return On Assets of 1.70%. This is amongst the best in the industry. ANIP outperforms 85.13% of its industry peers.
Looking at the Return On Equity, with a value of 3.37%, ANIP belongs to the top of the industry, outperforming 86.15% of the companies in the same industry.
The Return On Invested Capital of ANIP (5.00%) is better than 83.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.7% | ||
| ROE | 3.37% | ||
| ROIC | 5% |
ROA(3y)-3.45%
ROA(5y)-2.78%
ROE(3y)-7.72%
ROE(5y)-6.37%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 3.16%, ANIP belongs to the best of the industry, outperforming 84.62% of the companies in the same industry.
ANIP's Profit Margin has declined in the last couple of years.
ANIP has a better Operating Margin (9.87%) than 82.05% of its industry peers.
ANIP's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 62.73%, ANIP is in the better half of the industry, outperforming 67.18% of the companies in the same industry.
ANIP's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.87% | ||
| PM (TTM) | 3.16% | ||
| GM | 62.73% |
OM growth 3YN/A
OM growth 5Y-10.86%
PM growth 3YN/A
PM growth 5Y-15.97%
GM growth 3Y2.53%
GM growth 5Y-0.34%
2. Health
2.1 Basic Checks
ANIP has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for ANIP has been increased compared to 1 year ago.
ANIP has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ANIP has been reduced compared to a year ago.
2.2 Solvency
ANIP has an Altman-Z score of 2.92. This is not the best score and indicates that ANIP is in the grey zone with still only limited risk for bankruptcy at the moment.
ANIP has a better Altman-Z score (2.92) than 75.38% of its industry peers.
The Debt to FCF ratio of ANIP is 2.59, which is a good value as it means it would take ANIP, 2.59 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of ANIP (2.59) is better than 91.79% of its industry peers.
A Debt/Equity ratio of 0.62 indicates that ANIP is somewhat dependend on debt financing.
The Debt to Equity ratio of ANIP (0.62) is worse than 65.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.62 | ||
| Debt/FCF | 2.59 | ||
| Altman-Z | 2.92 |
ROIC/WACC0.54
WACC9.23%
2.3 Liquidity
ANIP has a Current Ratio of 3.57. This indicates that ANIP is financially healthy and has no problem in meeting its short term obligations.
ANIP has a Current ratio of 3.57. This is comparable to the rest of the industry: ANIP outperforms 52.82% of its industry peers.
ANIP has a Quick Ratio of 2.81. This indicates that ANIP is financially healthy and has no problem in meeting its short term obligations.
ANIP has a Quick ratio (2.81) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.57 | ||
| Quick Ratio | 2.81 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 234.75% over the past year.
ANIP shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.38% yearly.
The Revenue has grown by 53.84% in the past year. This is a very strong growth!
ANIP shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.28% yearly.
EPS 1Y (TTM)234.75%
EPS 3Y10.48%
EPS 5Y-1.38%
EPS growth Q2Q31.58%
Revenue 1Y (TTM)53.84%
Revenue growth 3Y32.66%
Revenue growth 5Y19.28%
Revenue growth Q2Q39.76%
3.2 Future
Based on estimates for the next years, ANIP will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.26% on average per year.
Based on estimates for the next years, ANIP will show a small growth in Revenue. The Revenue will grow by 5.59% on average per year.
EPS Next Y-3.4%
EPS Next 2Y4.4%
EPS Next 3Y6.44%
EPS Next 5Y8.26%
Revenue Next Year12.16%
Revenue Next 2Y9.84%
Revenue Next 3Y8.54%
Revenue Next 5Y5.59%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 13.85, ANIP is valued correctly.
Based on the Price/Earnings ratio, ANIP is valued cheaper than 88.21% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 24.84, ANIP is valued a bit cheaper.
The Price/Forward Earnings ratio is 14.34, which indicates a correct valuation of ANIP.
86.15% of the companies in the same industry are more expensive than ANIP, based on the Price/Forward Earnings ratio.
ANIP's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 21.35.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.85 | ||
| Fwd PE | 14.34 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ANIP is valued cheaply inside the industry as 81.03% of the companies are valued more expensively.
89.74% of the companies in the same industry are more expensive than ANIP, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.46 | ||
| EV/EBITDA | 13.24 |
4.3 Compensation for Growth
The decent profitability rating of ANIP may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.4%
EPS Next 3Y6.44%
5. Dividend
5.1 Amount
ANIP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ANI PHARMACEUTICALS INC
NASDAQ:ANIP (4/26/2024, 7:00:00 PM)
After market: 62.35 -3.01 (-4.61%)65.36
+0.41 (+0.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.37B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.85 | ||
| Fwd PE | 14.34 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.7% | ||
| ROE | 3.37% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 9.87% | ||
| PM (TTM) | 3.16% | ||
| GM | 62.73% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.62 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.57 | ||
| Quick Ratio | 2.81 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)234.75%
EPS 3Y10.48%
EPS 5Y
EPS growth Q2Q
EPS Next Y-3.4%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)53.84%
Revenue growth 3Y32.66%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y